1 / 9

L. Silvestry et al . 2010. Minerva Anestesiol 76:193–202

Topical oropharyngeal vancomycin to control methicillin resistant Staphylococcus aureus lower airway infection in ventilated patients. L. Silvestry et al . 2010. Minerva Anestesiol 76:193–202. Mark Lopez Yessenia Velazco Micr 454L 04/07/10. Objectives.

shelagh-kennefick
Télécharger la présentation

L. Silvestry et al . 2010. Minerva Anestesiol 76:193–202

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Topical oropharyngeal vancomycin to control methicillin resistant Staphylococcus aureus lower airway infection in ventilated patients L. Silvestry et al. 2010. Minerva Anestesiol 76:193–202 Mark Lopez Yessenia Velazco Micr 454L 04/07/10

  2. Objectives • To evaluate the effectiveness of two different policies for topical vancomycin administration on oropharyngeal carriage and lower airway infection due to MRSA. • To monitor the emergence of vancomycin-resistant enterococci (VRE) and vancomycin-intermediate Staphylococcus aureus (VISA).

  3. Experimental Approach • Subject population: July 2002 – June 2005 Patients over 18 years old Required mechanical ventilation for >72 hours. • Study intervention: Period one (07/2002 – 12/2003)Vancomycin to all MRSA carriers Period two (01/2004 – 06/2005) Vancomycin to all patients • Antibiotic and non antibiotic policies of the unit: SDD (enteral and parental antimicrobials, hygiene, and surveillance culture of throat and rectum) • Microbiology: Columbia plus 5% sheep blood, mannitol salt agar, McConkey, Chocolate Haemophilus, Columbia colistin-nalidixic acid plus 5% sheep blood, and yeast agar • Statistical analysis: Fisher’s exact test, Chi-square (X2), Student’s t-test Significance was set at 0.05

  4. Results Figure 1. Oropharyngeal carriage indices of MRSA. CI: carriage index

  5. Main Findings • The immediate administration of topical oropharyngeal vancomycin on ICU admission significantly reduced the levels of MRSA carriage and lower airway infection compared with patients whom topical oropharyngeal vancomycin was only given after MRSA carriage was detected. • Neither VRE nor VISA were isolated from surveillance and diagnostic samples during the study period.

  6. Discussion • The effectiveness of MRSA carriage prophylaxis over MRSA carriage treatment may be explained by: 1. MRSA carriage treatment caused delay and promoted overgrowth, colonization, and subsequent infection of the lower airways 2. MRSA carriage prophylaxis protected patients against MRSA acquisition, and MRSA found during admission was cleared promptly by vancomycin administration. • Treatment of populations without MRSA may lead to the development of more resistant strains of MRSA • No evidence of vancomycin-resistant strains found in test subjects.

  7. Critiques • Two different consecutive time periods of data acquisition -Epidemiological changes in frequency of MRSA in general population -Contamination • No control group given placebo -Cannot say with certainty that changes in MRSA frequency are due to vancomycin treatment • Variations in sample populations -Differing underlying medical issues may increase or decrease vulnerability to MRSA

  8. Take Home Message 1. Prophylactic treatment of populations with vancomycin is more effective at controlling MRSA outbreaks than treatment of individual MRSA infections. 2. Treatment with vancomycin may reduce or eliminate MRSA infections in the short term, but may cause problems in the future by encouraging more resistant forms of MRSA to develop.

  9. Questions?

More Related